Johnathan Joffe

4.5k total citations · 1 hit paper
36 papers, 1.8k citations indexed

About

Johnathan Joffe is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Johnathan Joffe has authored 36 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 15 papers in Pulmonary and Respiratory Medicine and 10 papers in Oncology. Recurrent topics in Johnathan Joffe's work include Testicular diseases and treatments (16 papers), Sarcoma Diagnosis and Treatment (7 papers) and Ovarian cancer diagnosis and treatment (4 papers). Johnathan Joffe is often cited by papers focused on Testicular diseases and treatments (16 papers), Sarcoma Diagnosis and Treatment (7 papers) and Ovarian cancer diagnosis and treatment (4 papers). Johnathan Joffe collaborates with scholars based in United Kingdom, United States and France. Johnathan Joffe's co-authors include Janine Mansi, David Cunningham, A. Norman, Peter Harper, J. Oates, Andrew Webb, J.H. Scarffe, Tamas Hickish, MC Nicolson and Andrew Hill and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and The Lancet Oncology.

In The Last Decade

Johnathan Joffe

36 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1997 691 citations Andrew Webb, David Cunningham et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Johnathan Joffe United Kingdom	17	1.2k	835	827	305	235	36	1.8k
Núria Laínez Spain	16	672 0.6×	327 0.4×	432 0.5×	141 0.5×	353 1.5×	77	1.1k
Tatsuo Matsuda Japan	19	716 0.6×	781 0.9×	727 0.9×	207 0.7×	318 1.4×	47	1.8k
Alejandro Majlis Chile	14	1.9k 1.5×	1.3k 1.5×	892 1.1×	182 0.6×	637 2.7×	20	2.4k
L. Chaigneau France	21	927 0.8×	998 1.2×	251 0.3×	186 0.6×	67 0.3×	100	1.8k
Cécile Guillemet France	17	964 0.8×	507 0.6×	203 0.2×	130 0.4×	280 1.2×	64	1.4k
Olivier Collard France	16	1.1k 0.9×	681 0.8×	182 0.2×	145 0.5×	116 0.5×	67	1.6k
Richard Quek Singapore	22	591 0.5×	735 0.9×	198 0.2×	206 0.7×	162 0.7×	64	1.5k
Krystyna Kiel United States	20	1.3k 1.1×	622 0.7×	1.2k 1.5×	100 0.3×	65 0.3×	42	2.2k
Palma Dileo United Kingdom	18	1.6k 1.4×	850 1.0×	243 0.3×	264 0.9×	179 0.8×	52	2.0k
Pat Cook United Kingdom	14	1.1k 1.0×	243 0.3×	1.7k 2.1×	424 1.4×	408 1.7×	23	2.3k

Countries citing papers authored by Johnathan Joffe

Since Specialization

Citations

This map shows the geographic impact of Johnathan Joffe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johnathan Joffe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johnathan Joffe more than expected).

Fields of papers citing papers by Johnathan Joffe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johnathan Joffe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johnathan Joffe. The network helps show where Johnathan Joffe may publish in the future.

Co-authorship network of co-authors of Johnathan Joffe

This figure shows the co-authorship network connecting the top 25 collaborators of Johnathan Joffe. A scholar is included among the top collaborators of Johnathan Joffe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johnathan Joffe. Johnathan Joffe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Joffe, Johnathan, et al.. (2020). Evaluation of the “Shared Community Follow‐up” after a germ cell tumour—A novel initiative for remote cancer follow‐up enhanced by online patient‐reported outcome measures. European Journal of Cancer Care. 29(5). e13264–e13264. 2 indexed citations

Joffe, Johnathan, et al.. (2020). 794P UK practices for treatment of relapse in seminoma testicular cancer. Annals of Oncology. 31. S603–S603. 1 indexed citations

Jones, Robert H., Angela Casbard, Margherita Carucci, et al.. (2020). Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. The Lancet Oncology. 21(3). 345–357. 159 indexed citations

Cragg, William J, Fay Cafferty, Carlos Díaz-Montaña, et al.. (2019). Early warnings and repayment plans: novel trial management methods for monitoring and managing data return rates in a multi-centre phase III randomised controlled trial with paper Case Report Forms. Trials. 20(1). 241–241. 2 indexed citations

Watson, Robert, Hugo De La Peña, Maria Tsakok, et al.. (2018). Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK. British Journal of Cancer. 119(9). 1044–1051. 37 indexed citations

Shamash, Jonathan, Shah‐Jalal Sarker, Robert Huddart, et al.. (2017). A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). Annals of Oncology. 28(6). 1333–1338. 15 indexed citations

Huddart, Robert, Johnathan Joffe, Jeff White, et al.. (2017). 111: A single-arm trial evaluating one cycle of BEP as adjuvant chemotherapy in high-risk, stage 1 non-seminomatous or combined germ cell tumors of the testis (NSGCTT).. Journal of Clinical Oncology. 35(6_suppl). 400–400. 7 indexed citations

Harnden, Patricia, Johnathan Joffe, & William G. Jones. (2013). Germ Cell Tumours V. 3 indexed citations

Payne, Sarah, Janine Mansi, Alison Jones, et al.. (2013). Discordance between cancer prevalence and training: a need for an increase in oncology education. Clinical Medicine. 13(1). 50–56. 15 indexed citations

10.

Murray, Matthew J., Nicolas M. Orsi, Michele Cummings, et al.. (2013). Age‐related biological features of germ cell tumors. Genes Chromosomes and Cancer. 53(3). 215–227. 19 indexed citations

11.

Oliver, R. Timothy D., Graham M. Mead, Gordon Rustin, et al.. (2011). Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214). Journal of Clinical Oncology. 29(8). 957–962. 178 indexed citations

12.

Wah, Tze Min, et al.. (2011). Urethral metastasis from non-seminomatous germ cell tumor: a case report. Journal of Medical Case Reports. 5(1). 12–12. 2 indexed citations

13.

McIllmurray, M B, et al.. (2008). Vinorelbine and Infusional 5-fluorouracil in Anthracycline and Taxane Pre-treated Metastatic Breast Cancer. Clinical Oncology. 20(2). 152–156. 8 indexed citations

14.

Huddart, Robert, Michael O’Doherty, Anwar R. Padhani, et al.. (2007). ¹⁸ Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients With High-Risk, Clinical Stage I Nonseminomatous Germ Cell Tumors: Preliminary Report of MRC Trial TE22—The NCRI Testis Tumour Clinical Study Group. Journal of Clinical Oncology. 25(21). 3090–3095. 68 indexed citations

15.

Naik, Jay, et al.. (2006). High‐dose chemotherapy with haematopoietic stem‐cell support in patients with poor prognosis, relapsed or refractory germ cell tumours. British Journal of Urology. 98(3). 519–525. 2 indexed citations

16.

Harnden, Patricia, Johnathan Joffe, & William G. Jones. (2002). Germ Cell Tumours V. 1 indexed citations

17.

Waters, Justin S., A. Norman, David Cunningham, et al.. (1999). Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. British Journal of Cancer. 80(1-2). 269–272. 221 indexed citations

18.

Banks, Rosamonde E., M A Forbes, Meenu Wadhwa, et al.. (1997). Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines. British Journal of Cancer. 75(12). 1842–1848. 4 indexed citations

19.

Joffe, Johnathan, et al.. (1996). Cytokines in Combination with Chemotherapy for Advanced Renal Carcinoma - The Importance of Patient Selection. Cancer Biotherapy and Radiopharmaceuticals. 11(5). 309–313. 3 indexed citations

20.

Fosså, Sophie D., Monica Jones, Peter Johnson, et al.. (1995). Interferon‐alpha and survival in renal cell cancer. British Journal of Urology. 76(3). 286–290. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact